Davidson Matt sold AZR
November 2, 2026 · Form 4 insider transaction
Davidson Matt sold 524.954 shares of Adial Pharmaceuticals Inc at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
Subject to certain beneficial ownership and other limits set forth in the Certificate of Designation of the Series A Preferred Stock, each share of Series A Preferred Stock converted into 1,000 shares of the Issuer's common stock and has no expiration date.; The Series A Preferred Stock converted automatically within three days of Issuer's stockholders approving a proposal for the issuance of Issuer common stock upon conversion of the Series A Preferred Stock pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer, Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer, and a private Delaware corporation that was then known as Azora Therapeutics, Inc.